肾移植候选者与受者的抗血栓治疗管理:ERBP临床实践文件
该文件由ERA的DESCaRTES工作组与ESOT的EKITA委员会专家依据ERBP指南制定,针对晚期CKD及肾移植受者抗血栓治疗证据冲突、且被大型随机对照试验排除的现状,经系统文献综述汇总流行病学、病理生理学及相关研究,支持临床决策。
要点
- 晚期CKD与肾移植受者中血栓栓塞及动脉粥样硬化疾病常见,常需抗血栓治疗。
- 该人群被主要随机对照试验排除,抗血栓治疗最优管理仍不确定。
- 终末期肾病患者移植围手术期抗血栓管理需特别关注。
核心结论
- 晚期CKD及肾移植受者抗血栓治疗的最佳管理因证据冲突且缺乏大型随机对照试验数据而尚不明确。
- 该ERBP临床实践文件旨在支持临床医生对肾移植候选者与受者的抗血栓治疗做出决策。
研究设计与样本
- 由ERA的DESCaRTES工作组与ESOT的EKITA委员会专家依据ERBP指南制定的临床实践文件。
- 制定过程包括详细的系统文献综述。
主要发现
- 晚期CKD患者及肾移植受者中需抗血栓治疗的血栓栓塞与动脉粥样硬化疾病常见。
- 晚期CKD与肾移植受者被主要随机对照试验排除,相关证据存在冲突。
- 终末期肾病患者的移植围手术期抗血栓治疗管理需特别关注。
临床怎么用
- 用于支持临床医生对肾移植候选者与受者抗血栓治疗的决策。
- 需关注终末期肾病患者移植围手术期的抗血栓治疗管理。
局限性
- 证据存在冲突,且晚期CKD与肾移植受者被主要随机对照试验排除。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Thromboembolic and atherosclerotic disorders, necessitating antithrombotic therapies, are prevalent among patients with advanced chronic kidney disease (CKD), as well as in kidney transplant (KT) recipients. However, the optimal management of antithrombotic therapies in these patients remains uncertain due to conflicting evidence and the exclusion of advanced CKD and KT recipients from major randomized controlled trials. Additionally, the perioperative management of antithrombotic therapy in end-stage kidney disease patients undergoing transplantation requires specific attention. This clinical practice document prepared by experts from the DESCaRTES Working Group of the European Renal Association (ERA) and European Kidney Transplant Association (EKITA) from European Society of Organ Transplantation (ESOT) following European Renal Best Practice (ERBP) guidelines is designed to support clinicians in decision making on antithrombotic therapies in KT candidates and recipients. Following a detailed systematic literature review, it presents current knowledge in epidemiology and pathophysiology and summarizes all relevant studies in this topic.
引用
- Velioglu A, Karagiannidis AG, Demir E, et al. Management of antithrombotic therapies in kidney transplantation candidates and recipients: an ERBP clinical practice document by the DESCaRTES Working Group of ERA and the EKITA Committee of ESOT. Nephrol Dial Transplant. 2026. PMID: 41661128. doi:10.1093/ndt/gfag024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。